Revolution Medicines, Inc. (NASDAQ: RVMD) reported Q2 EPS of ($1.31), $0.19 worse than the analyst estimate of ($1.12).

For earnings history and earnings-related data on Revolution Medicines, Inc. (RVMD) click here.